Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.

2022 Startups to Watch
stats here
Related Posts on Startland News
2025 Startups to Watch: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
Editor’s note: Startland News editors selected 10 Kansas City scaling businesses to spotlight for its annual Startups to Watch list. Now in its 10th year, this feature recognizes founders and startups that editors believe will make some of the biggest, most compelling news in the coming 12 months. The following is one of 2025’s companies.…
2025 Startups to Watch: Marma pushes women’s nutrition to the forefront, birthing resources on demand
Editor’s note: Startland News editors selected 10 Kansas City scaling businesses to spotlight for its annual Startups to Watch list. Now in its 10th year, this feature recognizes founders and startups that editors believe will make some of the biggest, most compelling news in the coming 12 months. The following is one of 2025’s companies.…
2025 Startups to Watch: Noonan scores under par success with digital caddie as golf market earns deepage
Editor’s note: Startland News editors selected 10 Kansas City scaling businesses to spotlight for its annual Startups to Watch list. Now in its 10th year, this feature recognizes founders and startups that editors believe will make some of the biggest, most compelling news in the coming 12 months. The following is one of 2025’s companies.…
2025 Startups to Watch: OLEO roasts plans for slow-drip craft retail concepts, starting with coffee (and soon a diner)
Editor’s note: Startland News editors selected 10 Kansas City scaling businesses to spotlight for its annual Startups to Watch list. Now in its 10th year, this feature recognizes founders and startups that editors believe will make some of the biggest, most compelling news in the coming 12 months. The following is one of 2025’s companies.…

